Lombard Medical (EVAR) Tops Q2 EPS by 4c

Lombard Medical (NASDAQ: EVAR) reported Q2 EPS of ($0.51), $0.04 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $4.46 million.

Lombard Medical sees FY2015 revenue of $18-20 million.

"We had another solid quarter of rapidly growing procedures and revenues across key markets while making significant progress on our key commercial, regulatory and strategic initiatives," said CEO Simon Hubbert. "In the U.S., we added new physicians and new centers to our growing list of customers. We also launched Aorfix Plus, a new addition to our portfolio that allows us to treat patients with larger aortic neck diameters that we believe expands our addressable market by about 10 percent. In Japan, as a result of continued strong procedural growth, we estimate that we have captured approximately 5 percent market share within nine months of launching Aorfix."

For earnings history and earnings-related data on Lombard Medical (EVAR) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Bristol-Myers Squibb (BMY) stock slips despite earnings beat
• Associated Banc-Corp (ASB) Tops Q1 EPS by 3c